• CoenzymeQ₁₀ is a substance synthesized in all cells of the body which is necessary for synthesis of ATP, the substance that provides energy to all cells.
• CoenzymeQ₁₀ deficiency can be caused by reduced synthesis of CoQ₁₀ due to nutrient deficiencies or statin drug use, or by increased utilization of CoQ₁₀ by the body due to certain diseases, aging, or by an inflammatory atherogenic physiological state resulting from excess consumption of carbohydrates, calories and omega-6 fatty acids and inadequate intake of omega-3 fatty acids.
• The filling or diastolic phase of the heart cycle uses more energy than the contraction or systolic phase and CoQ₁₀ deficiency can cause impairment of the filling cycle of the heart leading to heart failure if not corrected. CoQ₁₀ supplementation to provide adequate CoQ₁₀levels can prevent diastolic heart failure. For those with diastolic dysfunction, CoQ₁₀supplementation will improve diastolic function and can normalize heart function if irreversible damage to heart muscle has not occurred. CoQ₁₀ also regenerates alpha-tocopherol to the active, reduced form.
• Ubiquinol, the reduced form of CoQ₁₀, is a potent anti-oxidant that helps protect cells of the body from oxidative damage. Increased oxidative stress due to aging, poor diet or inflammatory disease results in decreased levels of ubiquinol and total CoQ₁₀. The level of oxidative stress can be reduced by adoption of a good diet and by supplementation with CoQ₁₀ to increase the anti-oxidant protection available. For those who have coronary artery disease, these measures will reduce the progression of the disease and reduce the risk of plaque rupture.
• Those with conditions such as type-2 diabetes, asthma, arthritis and hypertension, and those over 65 years of age or taking statin drugs, are likely to be CoQ₁₀ deficient and would therefore benefit from CoQ₁₀ supplementation. CoQ₁₀ is a substance that occurs naturally in the body so there are no significant side effects. While it would be desirable to have blood levels tested, there are very few labs in the US capable of accurately testing CoQ₁₀ levels.

Coenzyme Q₁₀ is a fat-soluble vitamin-like substance present in every cell of the body, which serves as a coenzyme for several of the key enzymatic steps in synthesis of ATP on which production of energy within all cells depends. In its reduced form, called ubiquinol, Coenzyme Q₁₀ is a potent anti-oxidant that protects cells from damage by free radicals. It also regenerates other anti-oxidants, including vitamins C and E.

CoQ₁₀ was first isolated from beef heart mitochondria in 1957, and it was first synthesized in 1958. In 1972, Gian Paolo Littaru of Italy along with Professor Karl Folkers of the US documented a deficiency of CoQ₁₀ in human heart disease. By the mid 1970s, the Japanese had perfected the industrial technology to produce pure CoQ₁₀ in quantities sufficient for larger studies.

In the early 1980s, scientists were able to conduct a number of clinical trials due to the availability of CoQ₁₀ in large quantities from Japan and from the newly acquired capacity to measure CoQ₁₀ in blood and tissue. Professor Karl Folkers received the Priestly Medal in 1986 and the National Medal of Science from President Bush in 1990 for his work with CoQ₁₀ and other vitamins. Internationally, a dozen placebo controlled studies on treatment of heart disease with CoQ₁₀ have confirmed the effectiveness of CoQ₁₀ in improving heart muscle function while producing no adverse side effects or drug interactions.

Because CoQ₁₀ is a natural substance, it can not be patented, so patent-protected profits have not been available to educate physicians and the public about the proven benefits of CoQ₁₀ for the treatment of heart failure. The lack of patent-protected profits has also prevented the automation of the complex, seventeen-step process required for measurement of CoQ₁₀ blood levels by gas chromatography. Even today, only a half dozen labs in the United States are capable of testing CoQ₁₀ levels. CoQ₁₀ has shown great promise in preliminary studies in treatment of many other conditions, but lack of patent-protected profits and lack of an automated economical system for testing CoQ₁₀ have severely limited large-scale clinical studies.1

CoQ₁₀ Deficiency

CoQ₁₀ is present in small amounts in a wide variety of foods but the dominant source of CoQ₁₀ in humans is biosynthesis. CoQ₁₀ required by blood cells is synthesized in the liver, while the majority of CoQ₁₀ synthesis occurs in cells throughout the body.

The biosynthesis of CoQ₁₀ is a complex multi-step process that requires at least seven vitamins (B2, B3, B5, B6, B12, C and folic acid) and several trace elements, and is, by its nature, highly vulnerable. Sub-optimal nutrient intake impairing CoQ₁₀ synthesis is almost universal, and deficiency of any of the vitamins or trace elements required for CoQ₁₀ synthesis can cause deficiency of CoQ₁₀. Decreased absorption of nutrients necessary for synthesis of CoQ₁₀ can be caused by aging,2 digestive problems such as irritable bowel syndrome,3 liver diseases,4 and many common prescription drugs5 including oral contraceptives6 and HRT.7

CoQ₁₀ synthesis can also be impaired by the widely prescribed HMG-CoA reductase inhibitors (statins) which block the synthesis of melovonic acid and thereby block synthesis of cholesterol, CoQ₁₀ and other compounds, such as squalene and isoprene, all of which are important to health.

Increased utilization of CoQ₁₀ by the body is the cause of low blood CoQ₁₀ levels seen in many conditions, including excessive exertion,1 hyperthyroidism,8 aortic valve stenosis,9 hypertrophic cardiomyoathy,10 diabetes,11 rheumatoid arthritis,12 lupus,13 HIV,1 asthma,14 certain cancers, 15 hyperlipidemia,16 and atherosclerosis.17

Researchers now consider CoQ₁₀ deficiency to be a significant cause of heart failure and coronary artery disease. CoQ₁₀ deficiency also is thought to contribute to cancer, infertility in men18 and migraine headache.19

Overview of Heart Failure

Much of the media coverage and advertising on the subject of heart disease is misleading, unbalanced or erroneous. The term “cardiovascular disease” is often carelessly used in public discourse as though it were synonymous with “heart disease,” thereby implying that all heart disease is due to blockage of coronary arteries. As a result of widespread misinformation, many incorrectly believe that all heart failure is the result of coronary artery disease.

The primary cause of impaired systolic function is heart muscle damage caused by reduced blood flow due to coronary artery disease. While the damage can result from chronic reduced blood flow through narrowed arteries, it is most often due to plaque rupture, which causes a sudden complete artery blockage that precipitates a heart attack. The common measure of systolic function is “ejection fraction,” the percent of ventricle volume discharged with each heart contraction. Systolic function is considered impaired when the ejection fraction is less than 45 percent compared to the normal range of 55 to 70 percent and the borderline range of 45 to 54 percent. Clinical trials of heart disease treatments have focused for decades on young men with “impaired” systolic function. It is now recognized that over 90 percent of cardiac deaths occur in men and women over 65 years of age, and more than half of cardiac deaths occur in those with “normal” systolic function.20

Past focus on impaired systolic function occurred largely because the importance of the filling phase of the heart cycle, the diastolic phase, had been little studied and was poorly understood. The term “diastolic heart failure,” meaning heart failure resulting from impaired diastolic function in those with “normal” ejection fraction, first appeared in clinical studies about ten years ago, and one medical texts described diastolic heart failure as a “new” type of heart failure.21 Diastolic dysfunction leading to diastolic heart failure is due primarily to deficiency of CoQ₁₀ which causes energy starvation of the heart.

Whenever systolic function is impaired, diastolic dysfunction is also present, and the degree of diastolic dysfunction has been found to more accurately predict the prognosis of systolic heart failure than ejection fraction, the common measure of systolic impairment. While coronary artery disease is the primary cause of heart failure with impaired systolic function, the conditions that lead to coronary artery disease also increase CoQ₁₀ utilization and can result in CoQ₁₀ deficiency and diastolic heart failure.

The mortality rate of heart failure cases with impaired systolic function is almost double the mortality rate of diastolic heart failure, but the total number of deaths due to the two conditions is approximately equal due to the greater number of those with diastolic heart failure.20

Causes Of Coronary Artery Disease (CAD)

There are many factors that contribute to development of atherosclerosis, but the primary cause is the profound changes that have taken place in the American diet during the past century, particularly:

• Imbalance in consumption of essential fatty acids (too little omega-3 as in fish, too much omega-6 as in corn oil, etc.) which has an adverse effect on the balance of eicosanoids (localized tissue hormones) that control many functions of the body and mind.
• Excess consumption of carbohydrates, particularly sugars and high fructose corn syrup.
• Eating too much (too many calories).
• Free radicals in processed liquid vegetable oils and trans fatty acids partially hydrogenated vegetable oils.
• Nutrient deficiencies.22

The typical American diet results in increased production of triglycerides (TG), decreased levels of HDL-cholesterol, and a preponderance of small, dense LDL-cholesterol particles, a condition referred to as the atherogenic lipid triad. The increase in the atherogenic potential of LDL arises from the increase in the number of small, dense LDL particles, not from the cholesterol content per se. Small dense LDL particles more easily penetrate the arterial wall, initiating atherosclerotic injury, which leads to the development of inflammation and plaque.23

The development of highly atherogenic, small dense LDL particles is thought to be due to high insulin levels and excess triglycerides that result from excessive carbohydrate and caloric intake and from an imbalance of essential fatty acids.24,25 Researchers have noted a high degree of correlation between the TG/HDL ratio, insulin intolerance, particle size and the presence of coronary artery disease. Because TG and HDL are commonly measured, the ratio TG/HDL is considered proxy for LDL particle size and a good indicator of the presence of coronary artery disease (CAD) and risk of adverse coronary events.26

High insulin levels cause insulin intolerance and diabetes, and together these greatly increase the risk of coronary artery disease. In one study, 58 percent of CAD patients were found to be insulin resistant, including 22 percent with diabetes. Diabetes and insulin intolerance greatly increase the risk of cardiac death.27

The increased oxidative stress resulting from coronary artery disease increases utilization of ubiquinol, the reduced form of CoQ₁₀, resulting in low levels of both total CoQ₁₀ and ubiquinol. Levels of ubiquinol in those with CAD have been found to be inversely proportional to triglyceride levels.15 Diabetes causes severe depression of CoQ₁₀ levels, and because development of CAD usually occurs slowly, diastolic heart failure is common in diabetic patients.

Other factors that contribute to atherosclerosis are smoking, inactivity and stress. The stress factor can result from an imbalance of essential fatty acids due to excess production of “bad” eicosanoids (hormones) that promote the “fight or flight response” and which cause an exaggerated response to normal daily stress. Exaggerated stress response can result in many physiological changes that contribute to coronary artery disease, including increased adrenaline production leading to constriction of blood vessels, increased blood clotting factors, and stimulation of smooth muscle cell production.22

In addition, trans fatty acids and nutrient deficiencies, particularly deficiency in vitamin A, make it difficult for the body to produce hormones needed for dealing with stress.

Adoption of a nutrient-dense, low-carbohydrate diet with a balance of essential fatty acids can profoundly shift the physiological state to one that is anti-atherogenic, with normalized insulin and lipid levels. Such improvements in diet will not significantly reverse established diabetes or coronary artery disease, but will reduce their rate of progression. It is not unusual for those who adopt a healthy low-carbohydrate diet to experience a reduction of the TG/HDL ratio by 50 to 75 percent, indicating a dramatic decrease in insulin resistance, inflammation, and levels of small LDL particles, and further indicating reduced risk of diabetes, coronary artery disease and adverse cardiac events.28

The beneficial effects of a nutrient-dense, low-carbohydrate diet with balanced essential fatty acids is seen in the low rates of diabetes and heart disease in those who follow this type of diet, such as those in some fishing villages in Japan and Intuit natives.29,30 Autopsies have found significantly lower levels of atherosclerosis in such populations compared to neighboring populations on diets containing modern processed foods.

Cholesterol performs many important functions in the body and cholesterol levels increase with age in response to increased need. Research indicates that those with cholesterol above 240 have better brain function and live longer than those with cholesterol below the prescribed “healthy” level of 200. The increased incidence of cancer observed in statin users may be due in part to reduced cholesterol levels, which result in reduced synthesis of vitamin D from sunlight.31,32 Saturated fat, which has been erroneously demonized as a cause of high cholesterol levels, does not stimulate insulin production and thus cannot cause increased cholesterol levels.22

The typical pro-atherogenic American diet has been made far worse by ill-advised government policies, which encourage increased consumption of carbohydrates and omega-6 polyunsaturated oils and discourage consumption of healthy saturated fat and protein. As a result, the majority of older people have some degree of atherosclerosis and many have coronary artery disease.

CoQ₁₀ Deficiency and Diastolic Dysfunction

The filling phase of the heart requires more energy than the contraction phase, and is therefore more sensitive to CoQ₁₀ deficiency. Energy starvation of the heart due to CoQ₁₀ deficiency causes stiffening of the heart walls in the left ventricle and results in impaired filling of the heart, or diastolic dysfunction. Fatigue or lack of energy is a common symptom of diastolic dysfunction. The stiffened heart walls increase energy requirements of the heart thereby increasing CoQ₁₀utilization and further depleting CoQ₁₀ reserves. A vicious cycle ensues. As diastolic dysfunction worsens, blood pressure and heart rate increase, the heart walls thicken, and pulmonary hypertension often develops. When diastolic dysfunction is sufficient to produce pulmonary congestion (that is, a damming up of blood into the lungs causing shortness of breath), congestive heart failure is said to be present. Estimates indicate that 15 percent of those under age 50 and 50 percent of those over age 70 have diastolic dysfunction, and more than half of those presenting with acute pulmonary congestion have diastolic heart failure.21

The finding that diastolic dysfunction is caused by CoQ₁₀ deficiency is not reflected in the majority of medical references. Mainstream medicine insists that diastolic dysfunction is due to many causes, including chronic hypertension, hypertrophic cardiomyopathy, aortic stenosis, coronary artery disease, diabetes and aging. All of the conditions considered “causes” of diastolic dysfunction increase utilization of CoQ₁₀ and cause CoQ₁₀ deficiency, and all can be improved with CoQ₁₀supplementation.

Systolic heart dysfunction caused by coronary artery disease and diastolic dysfunction due to CoQ₁₀ deficiency are both common in the older population. In a recent study of men and women over age 65, about 5 percent were diagnosed with heart failure. Of those with heart failure, 63 percent had normal systolic function or diastolic heart failure, while only 15 percent had borderline systolic function and 22 percent had impaired systolic function. Men outnumbered women by three to one in those with impaired systolic function, while women slightly outnumbered men in those with normal systolic function.20

Treatment Of Heart Disease With CoQ₁₀

The normal range of CoQ₁₀ in the blood is 0.6 to 2.0 mcg/ml. CoQ₁₀ levels in the low normal range are an indication of conditions that increase utilization or decrease synthesis of CoQ₁₀. Since CoQ₁₀deficiency is widespread, average levels of CoQ₁₀ are actually considered to be less than optimum. In many of the studies of heart disease treatment with CoQ₁₀, patients were given a fixed amount of CoQ₁₀ on the order of 100 mg/day. More recently it has become the practice of some physicians to adjust CoQ₁₀ dosage to achieve a minimum blood level of 2.0 mcg/ml. This usually requires dosages of from 200 to 500 mg per day. CoQ₁₀ supplements are divided into doses of no more than 150 mg each, usually taken with meals for most efficient absorption.³³

The symptoms of fatigue and activity impairment, myalgia, and cardiac arrhythmia frequently precede by years the development of congestive heart failure and are the result of diastolic dysfunction caused by CoQ₁₀ deficiency. Supplemental CoQ₁₀ is unique in its ability to improve diastolic dysfunction and bring about a normalization of blood pressure, heart rate and ventricular hypertrophy that are symptoms of diastolic dysfunction. Accordingly, conditions that cause diastolic dysfunction are addressed first below.34

Hyperthyroidism

An overactive thyroid causes a high rate of metabolism or energy use, which results in increased utilization of CoQ₁₀ and can result in CoQ₁₀ levels that are among the lowest detected in human diseases. Hyperthyroidism will lead to heart failure if not corrected. CoQ₁₀ supplementation can normalize cardiac function, but correction of thyroid production usually will normalize metabolism, CoQ₁₀ levels and diastolic function.8

Statin Drug Use

The depletion of the essential nutrient CoQ₁₀ by the popular cholesterol-lowering drugs, HMG CoA reductase inhibitors (statins) is dose related. A clinical trial in which subjects took 80 mg per day of atorvastatin (Lipitor) resulted in a reduction of CoQ₁₀ by 50 percent within 30 days. It was concluded that statin-induced CoQ₁₀ deficiency was the probable cause of the most commonly reported side effects of statins—muscle pain, exercise intolerance, and fatigue.35

Another clinical trial found that CoQ₁₀ deficiency caused by atorvastatin therapy worsened left ventricular diastolic function in most patients. CoQ₁₀ supplementation in patients with worsening diastolic function resulted in improved diastolic function.36

In a recent clinical study, patients who had been on statins for an average of 28 months were evaluated for adverse statin effects, including muscle pain, fatigue, shortness of breath, memory loss and peripheral neuropathy. All patients discontinued statins due to side effects and began supplemental CoQ₁₀ at an average of 240 mg per day. After a period of 22 months, patients experienced a decrease in fatigue from 84 to 16 percent, muscle pain from 64 to 6 percent, shortness of breath from 58 to 12 percent, memory loss from 8 to 4 percent and peripheral neuropathy from 10 to 2 percent. Heart function improved or remained stable in the majority of patients and there were no adverse consequences from statin discontinuation. It was concluded that statin-related side effects are far more common than previously recognized and are reversible with a combination of statin discontinuation and supplemental CoQ₁₀.37

Cholesterol performs many valuable functions in the body that can be impaired by reduction of cholesterol levels with statins. For example, cells in the brain produce cholesterol because the cholesterol molecule is too large to pass the brain-blood barrier.38 Statins can pass the blood-brain barrier and reduce brain levels of cholesterol. A recent clinical study found that those taking statins had minor impaired mental function compared to controls not on statins.39

Hypertension

Secondary hypertension, or hypertension from known causes, such as renal artery stenosis and hardened arteries, is the cause of less than 10 percent of hypertension, while hypertension from unknown causes, or “essential hypertension,” comprises the remaining 90 percent. Secondary hypertension increases the energy requirements of the heart, thereby increasing CoQ₁₀ utilization and resulting diastolic dysfunction. Standard dogma in cardiology has long held that diastolic dysfunction is caused by both secondary and essential hypertension, but evidence from treatment of hypertension with CoQ₁₀ suggests that diastolic dysfunction is the cause, not the result, of hypertension from unknown causes.

The vast majority of patients with hypertension have diastolic dysfunction regardless of whether the blood pressure is treated or untreated, or controlled or uncontrolled. Supplemental CoQ₁₀ is unique in its ability to improve diastolic dysfunction, and as diastolic function improves, blood pressure in patients taking anti-hypertensive drugs drifts down so that more than one fourth of patients attain normal blood pressure and require no more anti-hypertensive drugs. The remaining patients require substantially less anti-hypertensive drug therapy.

Patients with diastolic dysfunction have impairment of the filling phase of the cardiac cycle, which limits the ability to increase cardiac output, and cardiac output can only be increased by increasing heart rate and blood pressure. It has been postulated that the normalization of blood pressure which occurs as a result of CoQ₁₀ supplementation is the result of the normalization of diastolic function—the ability of the heart to expand and fill more—and thus increase cardiac output.40,41

There have been numerous studies using CoQ₁₀ for treatment of hypertension in patients not on anti-hypertensive drugs. In eight studies, the mean decrease in systolic blood pressure was 16 mmHg and in diastolic pressure, 10 mmHg.42

Other beneficial effects of CoQ₁₀ include reduction of endothelial dysfunction, peripheral resistance and blood viscosity, thereby reducing blood pressure and improving circulation and delivery of oxygen to tissues. CoQ₁₀ also normalizes blood pressure by reducing oxidative damage to cells through the anti-oxidant action of the reduced form of CoQ₁₀, ubiquinol.

Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy (HCM) is a genetic abnormality manifested by severe thickening of the left ventricle, a condition that increases energy requirements of the heart and increased utilization of CoQ₁₀. The resulting CoQ₁₀ deficiency can cause significant diastolic dysfunction with disabling cardiac symptoms and increased risk of sudden death at any age. In a clinical trial on HCM treatment with CoQ₁₀ supplementation, ventricular wall thicknesses were reduced by 25 percent to near normal levels and symptoms of diastolic dysfunction, including fatigue and shortness of breath, were greatly reduced.10

Heart Dysfunction In The Elderly

Current medical texts often list aging as one of the many causes of diastolic dysfunction. Diastolic dysfunction is common in the elderly due to increased oxidative stress. Diastolic dysfunction shows clear improvement with use of CoQ₁₀, even in those of advanced age. Elderly patients, average age 84 years, experienced significant improvement in diastolic dysfunction, exercise tolerance and quality of life when treated with an average CoQ₁₀ dose of 220 mg per day. These findings refute the common assertion that a stiff and non-compliant heart is a normal and irreversible aspect of the aging process.53

Congestive Heart Failure

The main clinical problems in patients with congestive heart failure are frequent hospitalizations due to the high incidence of life-threatening arrhythmias, pulmonary edema and other serious complications.

In a trial that studied the influence of longterm CoQ₁₀ treatment on patients with chronic heart failure receiving conventional treatment, patients were randomized to receive a placebo or 2 mg per kilogram of body weight per day CoQ₁₀. Compared to those in the placebo group, patients receiving CoQ₁₀ in addition to conventional therapy had 38 percent fewer hospitalizations, 61 percent fewer episodes of pulmonary edema, and 51 percent fewer episodes of cardiac asthma. The results showed that addition of CoQ₁₀ to conventional therapy significantly reduced hospitalizations for worsening heart failure and the incidence of serious complications.54

CoQ₁₀ for Heart Attack Patients

In a one-year, double-blind controlled trial of patients who had suffered a recent heart attack, the effects of 120 mg per day of CoQ₁₀ were compared with effects of a placebo. The two groups were similar with respect to the extent and history of their heart disease, and both groups were receiving “optimal lipid therapy” with about half the patients in each group taking 10 mg per day of Lovastatin. Compared to those in the placebo group, patients receiving CoQ₁₀ in addition to conventional therapy had 44 percent fewer episodes of total cardiac events, 44 percent fewer non-fatal infarctions, significantly lower cardiac deaths, 83 percent fewer patients reporting fatigue, and a significant decrease in markers of atherosclerosis.55

CoQ₁₀ for Diabetic Patients

Diastolic dysfunction often in the absence of coronary artery disease is more prevalent in diabetics than in the general population. It has been estimated that approximately 75 percent of those with diabetes will eventually die from some kind of heart problem, compared to 25 percent of the general population. CoQ₁₀ supplements of 200 mg per day have been found to improve blood pressure, glycemic control and endothelial (circulatory) function in patients with type-2 diabetes. Control of endothelial function is of great importance because of the prevalence of circulatory problems in diabetics.51,56

Conclusion

CoQ₁₀, a substance found in all cells of the body, is essential for using the energy you breath to make the cellular energy source ATP. CoQ₁₀ deficiency results in impaired heart function, particularly dysfunction of the filling phase of the heart cycle. Diastolic dysfunction is present in all heart failure, whether the heart failure is due primarily to CoQ₁₀ deficiency, coronary artery disease, or some other cause.

Synthesis of CoQ₁₀ declines with age due to decreased absorption of the nutrients needed for CoQ₁₀ synthesis and the increased utilization of CoQ₁₀ from a natural increase in oxidative stress. CoQ₁₀ synthesis can be further depressed by a number of congenital conditions such as type-1 diabetes and some autoimmune diseases, and by self-inflicted physiological conditions such as insulin intolerance, type-2 diabetes and coronary artery disease, all of which are caused by high insulin levels that result from a diet with excess carbohydrates and omega-6 fatty acids and inadequate omega-3. Thus, the misguided, “politically correct” dietary recommendations are a major contributor to coronary artery disease so prevalent in the western world. Depletion of CoQ₁₀levels can be exacerbated by many drugs that are widely prescribed to the elderly, particularly the cholesterol-lowering statins, which directly inhibit CoQ₁₀ synthesis.

CoQ₁₀ is naturally present in the body so CoQ₁₀ supplementation causes virtually no side effects. CoQ₁₀ supplementation can prevent development of diastolic dysfunction and the accompanying symptoms of hypertension and fatigue and, when used in conjunction with proper diet, can reduce the risk of coronary artery disease and diabetes. CoQ₁₀ supplementation is also thought to reduce the risk of many other diseases and conditions, including cancer, immune diseases, migraine headache, male infertility and the increased oxidative stress that occurs with aging.

Of course, the first line of defence should be a nutrient-dense traditional diet, including liver and raw animal foods, which supply the vitamins and minerals needed for synthesis of CoQ₁₀. These foods are just as important for protecting seniors as they are for building strong bodies in the young.

Sidebars

Coenzyme Q₁₀ And Cancer

Abnormally low plasma CoQ₁₀ levels have been found in patients with melanoma and cancer of the breast, lung and pancreas.^A Early studies have hinted that CoQ₁₀ may be effective in treating some cancers. In one study, six of 32 patients who took 90 mg per day of CoQ₁₀ showed partial tumor reduction. One of the six then began taking 390 mg per day, and within two months there was no mammographic evidence of the tumor.^B An additional three patients undergoing conventional treatment took 390 mg of CoQ₁₀ over three to five years. The results: in patient one, liver metastases disappeared; in patient two, the tumor in the pleural cavity disappeared; in patient three, there was no sign of cancer in the tumor bed nor of metastases.^C

Abnormally low concentrations of CoQ₁₀ were found to be a strong predictor of metastasis in patients with melanoma. Patients with melanoma and matched controls were followed over seven and one-half years. The average CoQ₁₀ levels of patients at baseline was 0.50 mcg/ml compared to 1.27 mcg/ml in controls. It was found than 33 percent of melanoma patients developed metastases during the follow-up period. The patients who developed metastases during follow-up had baseline CoQ₁₀ levels of 0.34 mcg/ml compared with a level of 0.57 mcg/ml in patients who did not develop metastases. Patients with low baseline CoQ₁₀ levels had an approximate eight-fold risk of metastatic disease compared with patients with high levels. It was concluded the baseline CoQ₁₀levels are a powerful and independent prognostic factor that can be used to estimate the risk for melanoma progression.^A The foregoing study suggests the probability that CoQ₁₀ supplementation may greatly reduce the risk of metastases in melanoma patients.

In cancer, abnormal cell growth occurs because cells have lost their ability to kill themselves, a process called apoptosis. A recent study suggests that supplementing with CoQ₁₀ can restore the ability of the cancer cell to kill itself. Gene analysis has found that the bci-2 genes regulate cell division and programmed cell death. Cells normally divide and unneeded or sick cells are eliminated, but in cancer there is a decrease in cell death and the cells keep dividing. Both CoQ₁₀and bci-2 are present in normal and malignant cells, but in cancer patients there is an over-expression of bci-2 and a deficiency of CoQ₁₀. Under these conditions, the cells can’t self destruct, resulting in cell proliferation. The researchers concluded that CoQ₁₀ supplementation helps restore the ability of cancer cells to kill themselves.^D

Another study found that CoQ₁₀ supplementation reduces the side effects of chemotherapy.^E

While no large long-term studies have yet been carried out on use of CoQ₁₀ to treat cancer, it would seem prudent and beneficial for cancer patients to take CoQ₁₀ supplements based on information available to date.

References for this sidebar

1. Rusciani L et al., Low Plasma Coenzyme Q₁₀ levels as an independent prognostic factor in melanoma progression. J .Am Academy Dermatology 2006.
2. Lockwood K et al., Partial and Complete Regression of Breast Cancer Related to Dosage of CoQ₁₀. Biochem Biophys Res Coomun 1994.
3. Lockwood K et al progress of Therapy of Breast Cancer with Vitamin Q₁₀ and Regression of Metastases. Biochem Biosphys Res Commun 1995.
4. www.breastcancerchoices.org/coQ₁₀.
5. Conklin K. Coenzyme Q₁₀ for prevention of anthrcycline-induced cardiotoxicity. Integrative Cancer Therapies 2005.

Coenzyme Q₁₀ and Food

Research indicates that the body requires replacement of about 500 mg per day of CoQ₁₀.^a The average CoQ₁₀ content of the western diet is about 5 mg per day, so for most people, food contributes only about 1 percent of daily CoQ₁₀ requirements—the balance comes from endogenous synthesis. The highest level of CoQ₁₀ is found in heart meat, and significant amounts are found in cold water fish, beef, pork, chicken and nuts. About 10 percent of daily CoQ₁₀requirements can be obtained by eating 12 ounces of beef or pork heart, two pounds of sardines or mackerel, three pounds of beef or pork, or four pounds of peanuts. Milk, eggs, and most grains and vegetables contain small amounts of CoQ₁₀.^b

Synthesis of CoQ₁₀ indispensably requires vitamins B₂, B₆, B₁₂, C, folic acid, niacin and pantothenic acid along with several trace elements, including selenium, which protects CoQ₁₀ from oxidation.^c,dDeficiencies in any of these nutrients can result in reduced synthesis of CoQ₁₀ and cause many other adverse effects as well. The vitamin and mineral content of foods is therefore of greater importance for maintaining CoQ₁₀ levels than their CoQ₁₀ content. Most of the foods that contain significant amounts of CoQ₁₀ are also rich in many of the nutrients required for CoQ₁₀ synthesis.

Synthesis of CoQ₁₀ declines with age.^e A study of plasma levels of CoQ₁₀ and vitamin B₆ in the elderly found that indicators of vitamin B₆ activity declined with age, and that CoQ₁₀ levels were directly related to levels of B₆ activity,^f indicating that reduced CoQ₁₀ levels result from low levels of vitamin B₆. Vitamin B₁₂ is also required for CoQ₁₀ synthesis, and absorption of B₁₂ declines with age. Advanced age therefore increases the importance of adequate intake of the nutrients required for synthesis of CoQ₁₀, including nutrient-dense foods like liver and raw animal foods as sources of vitamin B₆.

Many inflammatory conditions that result in oxidative stress and reduced CoQ₁₀ levels, such as insulin intolerance, diabetes and atherosclerosis, can be prevented or improved by proper diet. A balanced, healthy diet is necessary to provide the nutrients needed for optimum CoQ₁₀ synthesis and for maintenance of a physiological state that minimizes the oxidative stress that that leads to decreased CoQ₁₀ levels.

References for this sidebar

1. Ernster L, Dallner G: Biochemical, physiological and medical aspects of ubiquinone function. Biochem Biophys Acta, 1995; 1271; 195-204.
2. Weber C. et al, The coenzyme Q₁₀ content of the average Danish diet. Int J Vitam Nutr Res. 1997: 67: 123-129.
3. Langsjoen, PH: Introduction to Coenzyme Q₁₀: http://faculty.washington.edu/~ely/coenzQ10.html.
4. Reid GM: Candida Albicans and selenium: Med Hypothesis, 2003 Feb:60(2)188-9.
5. Kalen A et al: Age related changes I the lipid concentration of rat and human tissue, Lipids, 1989: 24: 579-584.
6. Kant AK, Relation of age and self reported medical condition status with dietary nutrient intake, J Am Coll Nutr 199 Feb: 18 (1): 69-76.

CoQ₁₀, Vitamin E, and Coronary Artery Disease

There are a number of forms of vitamin E that occur in foods, but alpha-tocopherol is the only form that is retained by the body in significant amounts and is therefore considered the form of vitamin E most important to health.43 CoQ₁₀ supplementation regenerates the oxidized form of alpha-tocopherol to the active reduced form. It has been hypothesized that CoQ₁₀ is essential for the beneficial function of alpha-tocopherol.44

For a long time vitamin E was assumed to act by decreasing the oxidation of small dense LDL particles, which play a key role in atherosclerosis initiation. However, it has been found that at the cellular level, vitamin E acts by inhibiting many reactions involved in progression of atherosclerosis, including inhibition of smooth muscle cell proliferation, platelet aggregation, monocyte adhesion, oxLDL uptake, cykotine production and superoxide production. Oxidation impairs the beneficial functions of alpha-tocopherol, so regeneration of alpha-tocopherol by CoQ₁₀ is important for preventing coronary artery disease.45

CoQ₁₀, Omega-3 and Heart Disease

More than 20,000 clinical studies have explored the health benefits of omega-3 fatty acids, a large portion of which related to treatment of heart disease. A study in Italy of over 11,000 heart attack patients found that one gram per day of omega-3 fatty acids significantly reduced the mortality rate in the coming years, a record far better than that experienced by statin drug users, and without the adverse side effects. While the beneficial functions of omega-3 fatty acids are multiple, the researchers concluded that the reduction of mortality resulting in the aforementioned study was the result of a reduction in cardiac arrhythmias. As a result of the study, use of omega-3 supplementation following myocardial infarction has become standard protocol in Europe.46

EPA and DHA, the long-chain omega-3 fatty acids which are most important to heart health, are not present in plant foods but are abundant in cold water fish. EPA can be synthesized by the body from the omega-3 fatty acids found in plant food, but it is questionable whether DHA can be synthesized in adequate amounts, if at all. Synthesis of EPA is impaired by excessive omega-6 and carbohydrate intake and by trans fats. It has been hypothesized that CoQ₁₀ may protect the sensitive DHA double bonds from destruction by oxidation.47

Animal studies illustrate that vitamin B6 and folate metabolism are linked with those of long-chain fatty acids. Furthermore, a human study indicated synergistic effects of folic acid and vitamin B6 together with omega-3 fatty acids on the atherogenic index.48 Omega-3 fatty acids therefore enhance CoQ₁₀ synthesis through enhancement of B vitamin metabolism.

The beneficial functions of alpha-tocopherol in inhibiting development of atherosclerosis are also brought about by supplementation with EPA and DHA. In addition, EPA and DHA supplements have been found to improve endothelial function and insulin resistance, reduce thrombosis, reduce triglycerides and increase HDL-cholesterol.49,50

CoQ₁₀ has been found to improve endothelial function and peripheral resistance, both of which indicate poor circulation when compromised, leading to coronary artery disease. CoQ₁₀supplementation also reduces triglyceride levels, glucose levels and insulin resistance and increases HDL levels.51,52

Aortic Stenosis

Aortic stenosis, the incomplete opening of the aortic valve, increases the work load on the heart, thereby causing CoQ₁₀ deficiency and diastolic dysfunction. A major cause of aortic stenosis is a bicuspid valve, a genetic abnormality in which the aortic valve has two cusps rather than the normal three cusps. Calcification and narrowing of a bicuspid aortic valve often begins in the fourth or fifth decade of life. Aortic stenosis can also occur in a normal valve, usually in the seventh and eighth decade of life, due to normal wear and tear. When symptoms of heart failure occur, valve replacement is the treatment of choice. Over half of valve replacements are in those with a bicuspid valve.

CoQ₁₀ supplementation greatly improves heart function in aortic stenosis. While there have been no published studies on treatment of aortic stenosis with CoQ₁₀, cardiologists in private practice have observed near normalization of heart function in patients with mild to moderate aortic stenosis using CoQ₁₀ treatment.57 The hypothesis that CoQ₁₀ supplements improve diastolic function by increasing ATP synthesis is illustrated by the fact that aoric stenosis patients have imparied ATP synthesis which normalizes after valve replacement.9

In practice, elderly aortic stenosis patients are often denied surgical valve replacement. An analysis of long-term survival of patients over 70 years of age found that only patients with high baseline risk had a significantly better three-year survival than patients denied surgical treatment. In low-risk patients, those denied valve replacement had better a better survival rate than those who had valve replacement.58

Valve replacement in those with high baseline risk usually results in improvement of diastolic function, but often significant diastolic dysfunction remains, as indicated by pulmonary hypertension. Thus, it is reasonable to conclude that those patients who do benefit from valve replacement would also benefit from CoQ₁₀ supplementation following valve replacement.

Laboratory Tests For Plasma CoQ₁₀

Measurement of blood levels of CoQ₁₀ can determine whether or not supplementation is needed, as well as the effectiveness of supplementation in raising CoQ₁₀ levels. Ubiquinol, the reduced form of CoQ₁₀, is a potent anti-oxidant that protects cells from damage by free radicals, and determination of the ratio of ubiquinol to total CoQ₁₀ provides a measure of the risk of coronary artery disease. The ratio of CoQ₁₀ to cholesterol indicates the level of protection of cholesterol against free radical damage. Vitamin E is also important because of the synergism between vitamin E and CoQ₁₀,

At present there are only three labs in the US that provide testing for CoQ₁₀ and three others that researchers use only for research. The most advance lab for CoQ₁₀ testing in the US is the Langsjoen Q₁₀ Laboratory, Inc., located in the Langsjoen Cardiology Clinic in Tyler, Texas. This extremely accurate, high-pressure liquid chromatography laboratory can measure total and reduced CoQ₁₀ levels in both blood and heart muscle. The unit also measures the ratio of CoQ₁₀ to cholesterol and vitamin E levels. The only other such laboratories are located in Italy and Japan.

Individuals can have CoQ₁₀ levels tested at the Langsjoen laboratory. Lab personnel can assist patients in arranging for samples to be drawn locally, preferably on a Monday. The samples must be shipped overnight packed in dry ice to the Langsjoen lab. Samples are tested and the results mailed to the patient. There is a significant degree of variation between individuals in absorption of CoQ₁₀ supplements, particularly among those with significant heart impairment, so determination of supplemented blood levels is important for optimal treatment.

References (Main Article)

1. Langsjoen, Peter H. Introduction to Coenzyme Q₁₀, http://faculty.washington.edu/ely/coenzQ10.html.
2. Willis R: Clinical implications of the correlation between coenzyme Q₁₀ and vitamin B6 status: Biofactors, 199;9(2-4);359-63.
3. Koutroubakis IE: Hyperhomocysteinemia in Greek patients with inflammatory bowel disease: Dig Dis Sci, 200 Dec:45(12)2347-51.
4. Bianchi GP: Reduced ubiquinone plasma levels in patients with liver cirrhosis and in chronic alcoholics: Liver, 1994 Jun;14(3):138-40.
5. Lukasik, RJ: Drug Induced Coenzyme Q₁₀ Deficiency: http://rejuvenation-science.com/coQ10-depletion.html.
6. Lussana F: Blood levels of homocysteine, folate, vitamin B6 and B12 in women using oral contraceptives compared to non-users: Thromb Res, 2003:112(1-2):37-41.
7. Smolder RG et al: Hormone replacement influences homocysteine levels in the methionine loadingtest: a randomized placebo controlled trial: Eur J Obstet Gynecol Reprod Biol, 2004 Nov 10:117(1):55-9.
8. Pandolfi C et al: Circulating levels of CoQ₁₀ in hypo-and hyperthyroidism: Minerva Endocrinol, 1994 Sep:19(3);139-42.
9. Beyerbacht HP et al: Aortic valve replacement in patients with aortic valve stenosis improves myocardial metabolism and diastolic function: Radiology, 2001 Jun:219(3);637-43.
10. Langsjoen PH, et al. Treatment of hypertrophic cardiomyopathy with Coencyme Q₁₀: Mol Aspects Med 1997;18 Suppl:S145-52.
11. Lim SC et al: Oxidateve burden in prediabetic and diabetic individuals: evidence from plasma coenzyme Q₁₀: Diabet Med. 2008 Dec;23(12):1344-9.
12. Gonzalez-Gay MA et al: Cardiovascular disease in rheumatoid arthritis: Bimoed Pharacother, 2006 Dec:60(10):673-7, Epub 2206 Oct 10.
13. Kurup RK et al:Hypothalamic-mediated model for system lupus erthematosis: relation to hemispheric chemical dominance. Int J Neurosci. 2003 Nov:113(11);1561-77.
14. Gazkik F et al: Decrease levels of coenymze Q₁₀ in patients with bronchial asthma: Allergy, 2002 Sep;57(9):811-4.
15. Portakal O et al: Coenzyme Q₁₀ concentrations and antioxidant status in tissues of breast cancer patients: Clin Biochem. 2000 Jun:33(4):279-84.
16. Kontush A eta al: Plasma ubiquinone decreased in patients with hyperlipidemia: Atherosclerosis 1997 Feb28;129(1):116-26.
17. Zakova P et al: Ubiquinol-10/lipids ratios inconsecutive patients with different angiographic findings: Clin Chim Acta, 2007 May 1:380(1-2):133-8. Epub 2007 Feb 2.
18. Mancini A et al, An update of coenzyme Q₁₀ implications in male infertility: Biochemical and therapeutic aspects. Biofactors, 2005;25(1-4):165-74.
19. Hershey AD et al, Coenzyme Q₁₀ deficiency and respose to supplementation in pediatric and adolescent migraine: Headache. 2007 Jan; 47(1):73-80.
20. Gottiener JS et al: Outcome of congestive heart failure in elderly persons: Influence of left ventricular systolic function. The Cardiovascular Health Study: Ann intern Med. 2002 Oct 15:137(8):631-9.
21. Fogoros RN: Diastolic Dysfunction: A new kind of heart failure? http://heartdisease.about.com.
22. Ottoboni, A and F: The Modern Nutritional Diseases and How to Prevent Them: Vincete Books Inc, Third Printing June 2004, pgs 25-54.
23. Griffin BA: Lipoprotein athrogenicity: and overview of current mechanisms: Proc Nutr Soc, 199 Feb:58(1);163-69.
24. Okopien B et al: The risk of atherosclerosis in patients with impaired glucose tolerance. Res Commun Moi Pathol Pharmacol, 2003:113-114:87-95.
25. Storlien LH et al: Fatty acids, triglyclerides and syndromes of insulin resistance. Prostoglandins Leukot Essent Fatty Acids. 1997 Oct;57(4-5):379-85.
26. Ostfeld R et al: Atryglyceride/High-density lipoprotein ratio >/= 3.5 is associated with an increased burden of coronary artery disease on cardiac catheterization: J Cardiometab Syndr, 2006 Winter;1(1):13-15.
27. Yamasa T et al: Evaluation of glucose tolerance, post-prandial hyperglycemia and hyperinsulinemia influencing the incidence of coronary artery disease. Intern Med. 2007;46(9):543-6. Epub 2207 May 1.
28. Kaufman, J. Malignant Medical Myths, Infinity Publishing, 2006, pgs 57-58.
29. Yamada T et al, Atherosclerosis and omega-3 fatty acids in the population of a fishing village and farming village in Jaapan: Atherosclerosis, 2000 Dec:153(2);469-81.
30. McLaughlin J et al: Adipose tissue triglyceride fatty acids and atherosclerosis in Alaska natives and non-natives. Atherosclerosis, 2005 Aug:181(2):353-62.
31. Elias PK et al: Serum cholesterol and cognitive performance in the Framingham Heart Study. Psychosom Med, 2005 Jan-Feb:67(1):24-30.
32. Okuyama H: Need tochange the direction of cholesterol-related medication – a problem of great urgency. Yakugaku Zasshi, 2005 Nov:125(11):833-52.
33. Langsjoen H et al: Usefulness of coenzyme Q₁₀ in clinical cardiology: a long term study; Mol Aspects Med. 1994;15 Suppl:s165-75.
34. Langsjoen PH et al: Isolated diastolic dysfunction of the myocardium and its response to CoQ₁₀ treatment: Clinc Investif 1993: 71(8Suppl):S140=4.
35. Rundek T et al: Atorvastatin decreases the coenzyme Q₁₀ level in the blood of patients at risk for cardiovascular disease and stroke. Arch Neurol. 2004 Jun;61(6):889-92.
36. Silver MA et al, Effect of atorvastatin on left ventricular diastolic function and ability of coenzyme Q₁₀ to reverse that dysfunction. Am J Cardiol, 2004 Nov 15;94(10):1306-10.
37. Langsjoen PH et al, treatement of statin adverse effects with supplemental Coenzyme Q₁₀ and statin drug discontinuation. Biofactors, 2005:25(1-4);147-52.
38. Mauch DH et al: CNS synapogenesis promoted by gliaderived cholesterol. Science, 2001 Nov 9:294(5545):1354-7.
39. Muldoon MF et al: Randomized trial of the effects of simvasatin on cognitive functioning in hypercholesterolemic adults. Am J Med 2004 Dec 1:117(11):823-9.
40. Langsjoen P et al, Treatment of Essential Hypertension with Coenzyme Q₁₀. Mol Aspects Med, 194:15 Suppl:s265-72.
41. Langsjoen PH: Comments on the hew hypertension guidelines: Discussion Jan 2003, www.thincs.org/disuss.jano3.htm.
42. Rosenfeldt F; Systematic review of effect of coenzyme Q₁₀ in physical exercize, hypertension and heart failure. Biofactors, 2003;18(1-4);91-100.
43. Zingg JM eta al: Non-anti-oxidant activities of vitamin E. Curr Med Chem, 2004 May;11(9):1113-33.
44. Coenzyme Q₁₀: Function of coenzyme Q₁₀: www.choesteroland-health.com/Coenzyme-Q10.html.
45. Munteanu A et al: Anti-atherosclerotic effects of Vitamin E Myth or reality? J Cell Mol Med, 2004 Jan-Mar8(1)59-75.
46. O’Keefe, JH et al, From Intuit to implementation: omega-3 fatty acids come of age. Mayo Clin Proc. 2000 Jun;75(6):607-14.
47. Ottoboni A and F: The Modern Nutritional Diseases and How to Prevent Them: Vincente Book Inc., Third printing June 2004, pg 165.
48. de Bree A et al: Evidence for a protective (synergistic?) effect of B-vitamins and omega-3 fatty acids on cardiovascular diseases. Eur J Clin Nutr, 2004 May;58(5):732-44.
49. Simopoulous AP, Essential fatty acids in health and chronic disease. Am J Clin Nutr 199 Sep:70(3 Suppl):560S-569S.
50. Pakala R eta al: Thromboxane A2 fails to induce proliferation of smooth muscle cells enriched with EPA and DHA. Prostoglandins Leukot Essent Fatty Acids, 1999 Apr;60(4):275-281.
51. Watts GF et al: Coenzyme Q₁₀ improves endothelial dysfunction of the brachial artery in Type 2 diabetes mellitus. Diabetologia, 2002 Mar;45(3):420-6.
52. McCarty MF: Coenzyme Q versus hypertension: Does CoQ decrease endothelial superoxide generation? Med hypothesis, 199 Oct;53(4):300-4.
53. Langsjoen PH et al: The Aging Heart; Reversal of Diastolic Dysfunction Through Use of Oral CoQ₁₀ in the Elderly. Anti-Aging Medical Therapeutics, 1997, Health Quest Publications, pp 113-120.
54. Morisco C et al: Effect of coenzyme Q₁₀ therapy in patients with congestive heart failure: a long-term multicenter randomized study.
55. Singh RB Effect of coenzyme Q₁₀ on risk of atherosclerosis in patients with recent myocardial infarction. Mol Cell Biochem, 2003 Apr;246(1-2)75-82.
56. Hodgson JM et al: Coenzyme Q₁₀ improves blood pressure and glycaemic control: a controlled trial in subjects with type 2 diabetes. Eur J Clin Nut 2002 Nov;56(11):1137-42
57. Langsjoen, PH, per personal conversations.
58. Bouma BJ et al: To operate or not operate on elderly patients with aortic stenosis: the decision and its consequences. Heart, 1999 Aug;82(2):143-8.

This article appeared in Wise Traditions in Food, Farming and the Healing Arts, the quarterly magazine of the Weston A. Price Foundation, Fall 2007.